Viatris Inc (VTRS)
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Viatris Inc.
- moderate-to-severe acute pain
Trials need funding. See this company's dilution risk and cash position.
- Phase 4Active, not recruiting
Dymista in Chinese Adolescents
Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate
Allergic Rhinitis Due to Allergens
NCT07597473Enrollment100StartMay 2026Primary CompletionOct 2026est.CompletionOct 2026est. - Phase 4Completed
Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience
Alprazolam (Xanax), Placebo
Healthy Non-dependent, Recreational Sedative Users
NCT07777965Enrollment44StartJun 2026Primary CompletionAug 2026CompletionAug 2026 - Phase 4Recruiting
Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users
Placebo, Oxycodone 20mg
Healthy
NCT07813026Enrollment60StartAug 2026Primary CompletionJan 2027est.CompletionFeb 2027est. - Phase 3Terminated
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment
Blepharitis
NCT06400511Enrollment477StartApr 2024Primary CompletionSep 2025CompletionOct 2025 - Phase 2Active, not recruiting
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
cenerimod 4 mg
SLE - Systemic Lupus Erythematosus
NCT07266090Enrollment15StartJan 2026Primary CompletionOct 2027est.CompletionOct 2027est. - Phase 1Unknown status
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)
Chronic Heart Failure
NCT06266988Enrollment48StartMar 2024est.Primary CompletionApr 2024est.CompletionAug 2024est. - Phase 1Unknown status
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
Bioequivalence Study
NCT06273254Enrollment48StartApr 2024est.Primary CompletionMay 2024est.CompletionSep 2024est. - ObservationalCompleted
Revatio Special Investigation for Long-term Use in Pediatric Patients
Sildenafil
Pulmonary Arterial Hypertension
NCT03364244Enrollment1,023StartNov 2017Primary CompletionAug 2022CompletionAug 2022 - ObservationalUnknown status
Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
Lyrica CR (Pregabalin)
Peripheral Neuropathic Pain
NCT04171453Enrollment600StartFeb 2020Primary CompletionJul 2022est.CompletionJul 2022est. - ObservationalActive, not recruiting
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Elidel 1% Topical Cream
Mild to Moderate Atopic Dermatitis
NCT06052995Enrollment130StartOct 2024Primary CompletionOct 2026est.CompletionMar 2027est. - ObservationalUnknown status
Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance
Dovprela
Dovprela
NCT06471088Enrollment100StartJul 2023Primary CompletionJun 2026est.CompletionJun 2026est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 4 | Active, not recruiting | Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate | NCT07597473 |
| Phase 4 | Completed | Alprazolam (Xanax), Placebo | NCT07777965 |
| Phase 4 | Recruiting | Placebo, Oxycodone 20mg | NCT07813026 |
| Phase 3 | Terminated | Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment | NCT06400511 |
| Phase 2 | Active, not recruiting | cenerimod 4 mg | NCT07266090 |
| Phase 1 | Unknown status | Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) | NCT06266988 |
| Phase 1 | Unknown status | Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg) | NCT06273254 |
| Observational | Completed | Sildenafil | NCT03364244 |
| Observational | Unknown status | Lyrica CR (Pregabalin) | NCT04171453 |
| Observational | Active, not recruiting | Elidel 1% Topical Cream | NCT06052995 |
| Observational | Unknown status | Dovprela | NCT06471088 |